rezvilutamide
3 abstracts
Abstract
Rezvilutamide (REZ) plus docetaxel (DOC) in patients (pts) with chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone (ABI).Org: Clinical Trial Center and National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China, Department of Urology Surgery, Hunan Cancer Hospital, Changsha, China, Uro-Oncology, Chongqing University Cancer Hospital, Chongqing, China, Urological Oncology, Sichuan Cancer Hospital, Chengdu, China, Urinary Surgery, The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University, Chongqing, China,
Abstract
Patient-reported outcomes (PROs) for rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC): An analysis of the CHART randomized, open-label, phase 3 trial.Org: Department of Urology Surgery, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Department of Urology, Sun Yat-sen University Cancer Center, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, The Second Affiliated Hospital of Xi'an Jiaotong University, The First Affiliated Hospital of the Army Medical University,
Abstract
A phase II umbrella clinical trial of advanced salivary gland cancer based on molecular typing.Org: Minimally Invasive Therapy Center,